Methyl aminolaevulinate?photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer
Author:
- 1 May 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 156 (5) , 793-801
Abstract
Methyl aminolaevulinate-photodynamic therapy (MAL-PDT) has advanced the management of nonmelanoma skin cancer (NMSC), providing a treatment option for actinic keratosis (AK), basal cell carcinoma [both superficial (sBCC) and nodular (nBCC)] and Bowen's disease, with good clinical outcomes, low recurrence rates and enhanced cosmetic acceptability. Excellent results have been reported, with complete responses (CRs) in AK ranging from 69% to 93% at 3 months; CRs in Bowen's disease are 93% at 3 months and 68% at 24 months. In sBCC, CRs range from 85% to 93% at 3 months and are comparable with cryosurgery up to 60 months (75% vs. 74%). In nBCC, CRs range from 75-82% at 3 months to 77% at 60 months. MAL-PDT specifically targets diseased cells, leaving healthy tissue unharmed. This noninvasive treatment option is associated with minimal risk of scarring. Moreover, systemic uptake of MAL is negligible and the local phototoxic reactions that often occur during treatment rapidly heal to produce excellent cosmetic results. The side-effects of therapy, which are predominantly local phototoxic effects (burning, stinging and prickling sensations), are of mild-to-moderate intensity, of short duration and easily managed. Overall, the efficacy and low risk of side-effects afforded by this therapy have resulted in high patient preference in clinical trials. The current evidence base for MAL-PDT in the treatment of AK and NMSC is reviewed in this article.Keywords
This publication has 38 references indexed in Scilit:
- Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled studyBritish Journal of Dermatology, 2006
- Porphyrin Formation in Actinic Keratosis and Basal Cell Carcinoma after Topical Application of Methyl 5-AminolevulinateJournal of Investigative Dermatology, 2006
- Paraneoplastic pemphigus: A brief updateAustralasian Journal of Dermatology, 2005
- Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatmentBritish Journal of Dermatology, 2003
- Keratinocyte CarcinomaCA: A Cancer Journal for Clinicians, 2003
- Current treatment patterns in non-melanoma skin cancer across EuropeJournal of Dermatological Treatment, 2003
- The role of light in the treatment of non-melanoma skin cancer using methyl aminolevulinateJournal of Dermatological Treatment, 2003
- The Majority of Cutaneous Squamous Cell Carcinomas Arise in Actinic KeratosesJournal of Cutaneous Medicine and Surgery, 2002
- Guidelines of care for actinic keratosesJournal of the American Academy of Dermatology, 1995
- Metastatic basal cell carcinoma: Report of twelve cases with a review of the literatureJournal of the American Academy of Dermatology, 1991